What does "30 percent decrease in the risk of death with 78 percent of patients surviving after six years of follow-up after treatment
with MEPACT" mean?
eliud thorn's List: Osteosarcoma Clinical Treatments
-
-
-
-
The approval was based on the Phase 3 MEPACT trial (INT-0133), a National Cancer Institute (NCI) funded cooperative group study conducted by the Children's Oncology Group (COG) and the largest study ever completed in osteosarcoma, enrolling approximately 800 patients. The study evaluated patient outcomes with the addition of MEPACT to three- or four-drug adjuvant chemotherapy (cisplatin, doxorubicin, and methotrexate with or without ifosfamide). Results demonstrated that the addition of MEPACT to chemotherapy resulted in approximately a 30 percent decrease in the risk of death with 78 percent of patients surviving after six years of follow-up after treatment with MEPACT.
-
-
-
Jul 21, 09
Therapy using one drug toxic to tumor and other cells, and one protective drug to protect good cells.
-
Aug 06, 09
Study regarding repeat pulmonary mets resection
-
In conclusion, patients with complete resection for recurrent pulmonary metastasis show a significantly better prognosis after repeat pulmonary metastasectomy. Our data imply that repeat pulmonary metastasectomy might be beneficial because it can salvage a subset of patients with osteosarcoma who retain favorable prognostic determinants.
-
-
List Comments
(0)
List Info
35 items | 8 visits
Information about orthodox or clinical treatments that may or may not be approved for use. Not trial information.
Updated on Jun 20, 11
Created on May 19, 09
Category: Health & Wellness
URL: